IMPRINT
Pantarhei Bioscience BV | Boulevard 17 | 3707 BK Zeist | The Netherlands
Phone: +31 (0)30 6 985 020 | Email: info@pantarheibio.com
DISCLAIMER
The information contained in this website is for general information purposes only. The information is provided by Pantarhei Bioscience and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
SOCIAL MEDIA
© 2021
Estetrol has DUAL efficacy in the treatment ofend-stage breast cancer
/in News /by Astrid van den HeuvelThe pregnancy estrogen Estetrol (E4) has a DUAL effect when treating heavily-pre-treated women with advanced breast cancer who have no further treatment options. First, E4 has an anti-tumor effect and second, E4 improves wellbeing.
The Dutch biotech company Pantarhei Oncology presents on December 13, 2019 at the San Antonio Breast Cancer Symposium (SABCS) in the USA the results of the first clinical study with High Doses of the fetal estrogen Estetrol (HDE4) in women with advanced end-stage breast cancer. Nine women without further treatment options participated in the study and were treated with 20, 40 or 60 mg E4 per day for 12 weeks. Anti-tumor effects after 12 weeks treatment were confirmed in 5 of 9 women and strong improvement of wellbeing occurred in 7 of 9 patients.
For more information please read the Press Release or the Poster.
Voor meer informatie lees hier het Nederlandstalig persbericht.
27th World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI), November 21-23, 2019, Paris
/in News /by Astrid van den HeuvelOn Friday November 22, 2019, Herjan Coelingh Bennink from Pantarhei lectured during the session: Breast cancer epidemic and hormonal replacement: What is the relationship?
The title of this special countercurrent lecture was: Treatment of advanced breast cancer with high dose estrogens.
For more information please read the abstract.
13th European Society of Gynecology (ESG) Congress, October 16-19 2019, Vienna, Austria
/in News /by Astrid van den HeuvelOn Thursday October 17, 2019, Herjan Coelingh Bennink of Pantarhei lectured on: “Estetrol for the treatment of advanced breast cancer” in a symposium entitled “Breast cancer: new challenges in diagnosis, pathogenesis and therapy”. The symposium was chaired by Xiangyan Ruan and Kerstin Rhiem.
For more information, please read the abstract.